scholarly journals Validation of Hepascore as a Predictor of Liver Fibrosis in Patients with Chronic Hepatitis C Infection

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Hamid Kalantari ◽  
Hannan Hoseini ◽  
Anahita Babak ◽  
Majid Yaran
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Chronic Hepatitis C ◽  
Total Bilirubin ◽  
Serum Levels ◽  
Hepatitis C Infection ◽  
Glutamyl Transferase ◽  
Sensitivity Specificity ◽  
Severe Fibrosis

Introduction. Liver biopsy is an invasive determinator for hepatic fibrosis. Serum biomarkers can probably be used as an alternative to liver biopsy in assessment of the degree of fibrosis in patients with chronic Hepatitis C. Method. Eighty patients with chronic Hepatitis C were included in the study using simple nonrandom sampeling metod. After fulfillment of liver biopsy, the patients were categorized according to the METAVIR Scoring system. The Hepascore algorithm is computed based on age, sex, and the serum levels of total bilirubin, -glutamyl transferase, 2-Macroglobulin, and hyaluronic acid. The spearman and ROC tests were used. Results. According to the liver biopsy results, 12, 25, 20, 7 and 16 patients had F0, F1, F2, F3, and F4, respectively. With regard to the 0.34 cut-off point Hepascore had 67%, 56%, 64%, and 56% sensitivity, specificity, respectively, positive prediction value (PPV), and negative prediction value (NPV), respectively, for diagnosis of significant fibrosis. For a Hepascore cut-off point 0.61, sensitivity, specificity, respectively, PPV and NPB 82%, 86%, 70%, and 92% in diagnosis of severe fibrosis. For a Hepascore cut-off point 0.84, sensitivity, specificity, PPV and NPB were respectively 100%, 97%, 89%, and 100% for diagnosis of cirrhosis. Conclusion. Hepascore has a high value in diagnosis of the level of fibrosis, particularly cirrhosis. Therefore, it can be used for primary screening of patients to determine the need for liver biopsy.

scholarly journals FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - a developing country's perspective in DAA era

2018 ◽  
Vol 12 (03) ◽  
pp. 178-182
Author(s):  
Uros Karic ◽  
Ivana Pesic-Pavlovic ◽  
Goran Stevanovic ◽  
Milos Korac ◽  
Natasa Nikolic ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Chronic Hepatitis C ◽  
Study Cohort ◽  
Hepatitis C Infection ◽  
Advanced Liver Disease ◽  
Non Invasive ◽  
Apri Score ◽  
Severe Fibrosis

Introduction: Chronic Hepatitis C Virus (HCV) infection leads to progressive fibrosis making fibrosis staging necessary in the evaluation of such patients. Different fibrosis scores are emerging as possible non-invasive alternatives for liver biopsy. The Fibrosis-4 Index (FIB-4) and AST to Platelet Ratio Index (APRI) scores are the most widely used and the most extensively tested. This study aims to determine if it was possible to accurately use these to identify patients that are unlikely to have severe fibrosis. Methodology: One hundred and forty-two patients with chronic hepatitis C infection who underwent liver biopsy since January 1st 2014 until May 31st 2017 at the Hospital for Infectious and Tropical Diseases in Belgrade were analyzed. The FIB-4 and APRI scores were calculated for each patient and compared to histologically determined fibrosis stage. Results: A comprehensive statistical analysis was conducted in order to compare patients with and without severe fibrosis and to evaluate the accuracy of the fibrosis scores. Patients with non-severe fibrosis were younger, had higher platelet counts and lower transaminase levels. FIB-4 had an AUC of 0.875 and the APRI score had an AUC of 0.861. No patients with severe fibrosis or cirrhosis had a FIB-4 lower than 1.08. FIB-4 was superior to APRI in identifying patients with severe fibrosis in the study cohort. Conclusion: FIB-4 was superior to APRI in the recognition of severe fibrosis. FIB-4 may prove very useful in identifying patients without advanced liver disease, especially if other non-invasive methods are inaccessible.

Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection

2007 ◽  
Vol 150 (2) ◽  
pp. 116-121 ◽  
Author(s):  
Tzy-Yen Chen ◽  
Yih-Shou Hsieh ◽  
Triang-Tiau Wu ◽  
Shun-Fa Yang ◽  
Chia-Jun Wu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Gene Polymorphism ◽  
Chronic Hepatitis C ◽  
Serum Levels ◽  
Hepatitis C Infection

Diagnostic value of liver biopsy in patients with chronic hepatitis C infection

2002 ◽  
Vol 36 ◽  
pp. 106
Author(s):  
Aurelie Fabre ◽  
Janice Main ◽  
Howard Thomas ◽  
Graham Foster ◽  
Robert Goldin
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Chronic Hepatitis C ◽  
Diagnostic Value ◽  
Hepatitis C Infection

scholarly journals A Prospective Analysis of the Prognostic Value of Biomarkers (FibroTest) in Patients with Chronic Hepatitis C

2006 ◽  
Vol 52 (10) ◽  
pp. 1887-1896 ◽  
Author(s):  
Yen Ngo ◽  
Mona Munteanu ◽  
Djamila Messous ◽  
Frederic Charlotte ◽  
Françoise Imbert-Bismut ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Biopsy ◽  
Chronic Hepatitis C ◽  
Prognostic Value ◽  
Survival Rates ◽  
Roc Curves ◽  
Hcv Infection ◽  
Disease Classification ◽  
Severe Fibrosis

Abstract Background: FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is an alternative to liver biopsy for determining the severity of chronic hepatitis C virus (HCV) infection. We compared the 5-year prognostic value of the FibroTest with biopsy staging for predicting cirrhosis decompensation and survival in patients with chronic HCV infection. Methods: Fibrosis stage was assessed on the same day by FibroTest and biopsy in a prospective cohort of 537 patients. Disease classification at baseline was 157 patients with severe fibrosis (FibroTest >0.58), 137 with moderate fibrosis (FibroTest 0.32–0.58), and 243 with no or minimal fibrosis (FibroTest <0.32). Results: In 64 untreated patients with severe fibrosis, survival without HCV complications was 73% [95% confidence interval (CI), 59%–086%; 13 complications], and survival without HCV-related death was 85% (95% CI, 73%–96%; 7 HCV deaths). Survival rates were higher in patients with moderate fibrosis, [99% (95% CI, 97%–100%; 1 complication; P <0.001) and 100% (no HCV death; P <0.001) for patients with and without HCV-related complications, respectively], and in patients with minimal fibrosis [100% (no complication; P <0.001 vs severe) and 100% (no HCV death; P <0.001 vs severe), respectively]. FibroTest was a better predictor than biopsy staging for HCV complications, with area under the ROC curves (AUROC) = 0.96 (95% CI, 0.93%–0.97%) vs 0.91 (95% CI, 0.85%–0.94%; P = 0.01), respectively; it was also a better predictor for HCV deaths: AUROC = 0.96 (95% CI, 0.93%–0.98%) vs 0.87 (95% CI, 0.70%–0.94%; P = 0.046), respectively. The prognostic value of FibroTest was still significant (P <0.001) in multivariate analyses after taking into account histology, treatment, alcohol consumption, and HIV coinfection. Conclusion: The FibroTest measurement of HCV biomarkers has a 5-year prognostic value similar to that of liver biopsy.

Sign in / Sign up

Export Citation Format

Share Document